Wet-milled aqueous dispersions of clorsulon intended for oral drench administration are processed as suspensions with a particle-size-control objective rather than as solutions with pH-adjusted solubility. The API is classified in the relevant veterinary pharmacopoeial monograph as practically insoluble in water; therefore process capability is defined by the ability to maintain a reproducible particle size distribution after milling, not by dissolution of the active in the mixer. A production-scale rotor-stator high-shear mixer is used to prepare the initial slurry, after which the batch is passed through an in-line bead mill containing yttrium-stabilised zirconia beads of 0.6 mm to 0.8 mm diameter. Laser diffraction testing according to USP 429 is performed on samples drawn from the recirculation loop; the release limit is product-specific and is established by comparative in vivo plasma exposure rather than by a fixed universal value. Published data for a single clorsulon drench particle size limit are limited, so manufacturer dossiers typically carry a bracketed cumulative volume fraction at 90% undersize with an upper boundary tied to the reference product. The milled suspension is stabilised with a hydrated suspending agent such as hydroxyethylcellulose or sodium carboxymethylcellulose at 0.15% w/v to 0.50% w/v, which introduces a low-shear yield stress. Apparent viscosity is measured with a rotational viscometer at 25 °C per USP 911; the target range is established by sedimentation-volume studies conducted at 25 °C and 40 °C according to the physical stability principles of USP 1151. Preservative selection for multi-dose oral drench containers is confirmed through preservative efficacy testing per USP 51, with particular attention to the surface-wetting co-solvents used to disperse the API. The terminal dosage form is filled into high-density polyethylene drench containers with a calibrated dispensing chamber; filled volume is checked per USP 698 and the suspension is resuspendability-tested before release.

What Constrains Sterile Filtration of Non-Aqueous Clorsulon Combination Injectables?

In the reference fixed-dose injectable, clorsulon is dissolved at 100 mg/mL together with ivermectin at 10 mg/mL in a non-aqueous glycerol formal/propylene glycol co-solvent system; the labelled subcutaneous dose is 1 mL/50 kg body weight. The vehicle must not be treated as a simple aqueous buffer: its elevated viscosity at 20 °C increases pressure drop across sterilising-grade membranes and reduces membrane permeability. The filtration train is therefore configured with a pre-filter of 0.45 µm followed by a 0.22 µm hydrophobic PVDF or PTFE membrane; differential pressure is held below the filter manufacturer’s maximum, generally 1.0 bar to 1.5 bar, to avoid breakthrough and extractables migration. Filter compatibility is evaluated after 24 h static contact with the vehicle and active solution, not with water alone, and the test protocol follows the principles of USP 1664 for polymeric components. Terminal steam sterilisation is not the default for this non-aqueous system; aseptic filtration followed by aseptic filling into sterilised glass vials or polymer bottles is required. The line is fitted with nitrogen sparging before filling because the ivermectin component is oxygen-sensitive; clorsulon is comparatively stable but its sulfonamide groups can be degraded by strong oxidising agents and acidic aqueous diluents. Aqueous dilution of the non-aqueous solution is an operational boundary: addition of water or saline may precipitate clorsulon because its water solubility is negligible. Release testing includes sterility per USP 71, bacterial endotoxins per USP 85, subvisible particulate matter per USP 788, and assay of both actives by a stability-indicating HPLC method. Batch records on production-scale filling lines frequently show the main process bottleneck as slow filtration flux through the sterilising cartridge rather than filling speed; a second sterile filter is therefore installed as a redundant filtration point when batch sizes exceed the validated filter capacity.

Oral tablet development for clorsulon centres on dry granulation when direct compression of micronised active produces erratic flow from the hopper and unacceptable weight variation on high-speed rotary presses. The dose strength is derived from the approved oral dose in cattle and sheep, and because the active is dosed in milligrams rather than micrograms, tablet weights commonly fall in the 250 mg to 1.0 g range depending on species and formulation. Roller compaction is used with a nitrogen-purged feed hopper when ambient relative humidity exceeds 60%; the granules are then screened through an oscillating mill fitted with a 0.8 mm or 1.0 mm screen. Precompression force and punch dwell time are adjusted on the tablet press to reduce capping; friability is tested per USP 1216 and hardness is reported as a cross-check only, not as a release criterion. The dissolution method must be developed with a surfactant because sink conditions are difficult to maintain in aqueous media; sodium lauryl sulfate at 0.5% w/v to 2.0% w/v is commonly evaluated during method development, with the final concentration justified by an analytical method validation report. Release testing follows USP 905 for uniformity of dosage units and USP 711 for dissolution. Water content is determined by USP 921, with an in-process limit established from granule stability data. Published data for clorsulon tablet compact hardness and tensile strength are limited, so formulation development is conducted as a design-of-experiments matrix covering roll force, roll speed, screen size, and magnesium stearate level; the lubricant is normally held at 0.5% w/w to 1.0% w/w because overlubrication retards wetting of the hydrophobic active.

On encapsulation lines, clorsulon is handled as a cohesive, low-solubility active rather than a free-flowing direct-fill powder. The active is first preblended with lactose monohydrate or microcrystalline cellulose in a bin blender at 70% of nominal capacity, then passed through a 0.5 mm or 1.0 mm mill to break agglomerates. Croscarmellose sodium at 2% w/w to 4% w/w is included as a disintegrant, and magnesium stearate is added at 0.5% w/w to 1.0% w/w in the final blending step. The blend is filled into hard gelatin or HPMC capsules using a dosator-type machine; fill weight is controlled by periodic check at intervals not exceeding 15 min and is compared against the validated acceptance range. Uniformity of dosage units is assessed by USP 905, and dissolution by USP 711 using the same surfactant-assisted medium developed for tablets. Capsule shell compatibility is confirmed by stress testing at 40 °C and 75% RH for HPMC shells or at lower relative humidity for hard gelatin shells when water activity of the powder blend exceeds 0.60. The main scale-up fault observed on encapsulation lines is weight variation caused by powder flooding after magnesium stearate overblending; this is controlled by monitoring blend bulk density per USP 616 and bulk powder flow through an orifice. The finished capsule product is intended for oral administration to cattle or sheep in regional markets where capsule dosage is preferred over drenching; batch size is limited by a uniform blend requirement, and the API input is adjusted for assay on dried basis.

When Clorsulon Granules Are Blended into Carriers for Feed-to-Mouth Dosing

Fluidised-bed granulation is applied when the final product must be metered onto feed or into an oral drenching gun as a free-flowing granule rather than a suspension or tablet. The active is first dry-blended with lactose monohydrate or corncob carrier in a high-shear mixer; the binder solution, typically povidone K30 at 3% w/w to 5% w/w solids or hydroxypropyl methylcellulose at 2% w/w to 4% w/w, is sprayed from a top-spray nozzle at a rate that maintains a product temperature between 30 °C and 40 °C. Inlet air temperature is held at 55 °C to 65 °C; the final moisture after drying is monitored by USP 731 and is normally specified below 2.0% w/w. Particle size after sieving is controlled through USP 786; the median particle size is bracketed between 250 µm and 850 µm to limit segregation when granules are mixed into total mixed rations or free-choice mineral carriers. Segregation tendency is evaluated with a sampling thief at multiple points in a drum mixer and assayed by HPLC; if the relative standard deviation of blend samples exceeds 5.0%, the granule size distribution is narrowed or a lower carrier-to-granule ratio is used. The terminal product is a sachet or bulk granule pack with a labelled carryover time and feed-mixing rate; the manufacturing dossier must demonstrate that granules remain free-flowing after exposure to 75% RH for 24 h in a stability chamber. Because published feed-administered clorsulon granule data are limited, the in-process acceptance ranges are established by pilot-scale bracketing and are not extrapolated from oral suspension or tablet matrices.

Avoid Aqueous Dilution When Handling Non-Aqueous Clorsulon Injectables

Non-aqueous clorsulon injection concentrates are not designed for aqueous dilution at the farm or veterinary hospital level. The co-solvent system that keeps clorsulon in solution at 100 mg/mL is disrupted by water, saline, or lactated Ringer’s solution, causing precipitation of the active into subvisible particles that fail the particulate matter limits of USP 788. This incompatibility is not a simple preference but a phase-solubility boundary: clorsulon has practically negligible aqueous solubility, and the precipitation onset after dilution may be rapid or delayed depending on the proportion of water and the mixing temperature. In export documentation and technical data sheets, this operational limit must be stated prominently for veterinary pharmacy staff. The injectable product should be stored below 30 °C, protected from light, and used with dry syringes; residual moisture in reusable dosing equipment can produce localised precipitation at the needle hub. Product contact surfaces should be stainless steel or borosilicate glass; prolonged contact with unlined nitrile or natural rubber components may extract compounds into the non-aqueous vehicle and must be evaluated per USP 1664. Multi-dose vials, if used, require preservative efficacy testing per USP 51 because non-aqueous vehicles do not automatically prevent microbial growth after repeated needle puncture. The final packaging is nitrogen-flushed and sealed with an overseal; headspace oxygen is monitored in stability studies and the specification is set from the ivermectin oxidant sensitivity data rather than clorsulon degradation alone.